CD274 and non-small cell lung carcinoma: Our findings were implemented in the design of the planned stage 2 of the BR.36 trial, which uses ctDNA detection after two cycles of standard-of-care pembrolizumab monotherapy to identify patients with metastatic NSCLC with PD-L1 ≥50% at high risk for disease progression, who are subsequently randomized to treatment intensification with pembrolizumab and chemotherapy versus continuation of pembrolizumab.